pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

9,323 catalysts · 3,152 8k filing · 2,032 grant · 1,000 device adverse event · 910 approval · 674 device 510k · 584 earnings

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 45 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-01-29×clear all
type
  • 8k filing3,152
  • grant2,032
  • device adverse event1,000
  • approval910
  • device 510k674
  • earnings584
device pma
508
  • device recall215
  • phase 2 completion172
  • recall167
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Feb 2, 2026

    50
    ›Feb 4, 2026grant190d agoUNIVERSITY OF IOWA — Explaining the contagious nature of measles virusUniversity of Iowa

    AI grant. $791,990. PI: PATRICK L SINN

    full page →nih reporter ↗
    ›Feb 4, 2026grant190d agoICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — Fab-drug conjugates in transplant

    AI grant. $462,000. PI: Miguel Fribourg

    full page →nih reporter ↗
    ›Feb 4, 2026grant190d agoNEW YORK UNIVERSITY SCHOOL OF MEDICINE — Intestinal Programming of Gut-Associated Germinal CentersNew York University

    AI grant. $791,797. PI: Carla Rose Nowosad

    full page →nih reporter ↗
    ›Feb 4, 2026grant190d agoWASHINGTON UNIVERSITY — Exploring undefined roles of Calcineurin in restriction of autophagy-mediated...

    AI grant. $427,625. PI: Takeshi Egawa

    full page →nih reporter ↗
    ›Feb 4, 2026grant190d agoWASHINGTON UNIVERSITY — Defining the cellular basis of neurological dysfunction in models of ALG8 Con...

    NS grant. $37,249. PI: Haley Jetter

    full page →nih reporter ↗
    ›Feb 5, 2026approval189d agoAZTREONAM — FDA approvalAZTREONAM

    Sponsor: HIKMA. Form: INJECTABLE. Route: INJECTION

    full page →AZTREONAM →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: SAGENT PHARMS INC. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: SAGENT PHARMS INC. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: KINDOS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoNICOTINE POLACRILEX — FDA approvalPL Developments Copiague LLC

    Sponsor: P AND L. Form: GUM, CHEWING. Route: BUCCAL

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoNYSTATIN — FDA approvalActavis Mid Atlantic LLC

    Sponsor: STERANCO HLTHCARE. Form: SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: KINDOS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoBUMETANIDE — FDA approvalBUMETANIDE

    Sponsor: MSN. Form: TABLET. Route: ORAL

    full page →BUMETANIDE →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: ACCORD HLTHCARE. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: EUGIA PHARMA SPECLTS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: EUGIA PHARMA SPECLTS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoPRUCALOPRIDE SUCCINATE — FDA approvalSpecGx LLC

    Sponsor: TEVA PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoCARBIDOPA, LEVODOPA AND ENTACAPONE (CARBIDOPA) — FDA approvalcarbidopa

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →carbidopa →fda approvals ↗
    ›Feb 5, 2026approval189d agoMYQORZO (AFICAMTEN) — FDA approvalaficamten

    Sponsor: CYTOKINETICS. Form: TABLET. Route: ORAL

    full page →aficamten →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: ACCORD HLTHCARE. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoHYDROCORTISONE SODIUM SUCCINATE — FDA approvalHYDROCORTISONE SODIUM SUCCINATE

    Sponsor: APOTEX. Form: INJECTABLE. Route: INJECTION

    full page →HYDROCORTISONE SODIUM SUCCINATE →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: NOVAST LABS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: NOVAST LABS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 5, 2026approval189d agoZOLEDRONIC ACID — FDA approvalZOLEDRONIC ACID

    Sponsor: GLAND. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ZOLEDRONIC ACID →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026approval189d agoFLUOROURACIL — FDA approvalEfudex

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →Efudex →fda approvals ↗
    ›Feb 5, 2026device 510k189d agoEncora, Inc. — Encora X1 (510k cleared)Encore Inc.

    Product code: QBC. Advisory committee: Neurology. Type: Traditional

    full page →fda device 510k ↗
    ›Feb 5, 2026device 510k189d agoDentsply Sirona — Primevision 3D (510k cleared)DENTSPLY SIRONA Inc.

    Product code: OAS. Advisory committee: Radiology. Type: Traditional

    full page →fda device 510k ↗
    ›Feb 5, 2026device 510k189d agoGe Medical Systems, LLC — SIGNA™ Sprint Select (510k cleared)

    Product code: LNH. Advisory committee: Radiology. Type: Traditional

    full page →fda device 510k ↗
    ›Feb 5, 2026device 510k189d agoPenumbra, Inc. — INDIGO® Aspiration System - Lightning Flash Aspiration Tubing with LINK (510k cleared)Penumbra Inc

    Product code: QEW. Advisory committee: Cardiovascular. Type: Traditional

    full page →fda device 510k ↗
    ›Feb 5, 2026device 510k189d agoArgon Medical Devices, Inc. — CLEANER™ Vac Thrombectomy System, CLEANER™ Vac Aspiration Catheter with Handpiece, CLEANER™ Vac Aspiration Canister (510k cleared)

    Product code: QEW. Advisory committee: Cardiovascular. Type: Special

    full page →fda device 510k ↗
    ›Feb 5, 2026device pma189d agoW. L. Gore & Associates, Inc. — GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (PMA supplement)

    Supplement type: 30-Day Notice. Product code: PRL. Advisory committee: CV. Decision: OK30

    full page →fda device pma ↗
    ›Feb 5, 2026device pma189d agoAbbott Vascular (Idef Technologies Inc) — Supera Peripheral Stent System (PMA supplement)

    Supplement type: 30-Day Notice. Product code: NIP. Advisory committee: CV. Decision: OK30

    full page →fda device pma ↗
    ›Feb 5, 2026device pma189d agoArj Medical, Inc. — PyloPlus UBT System (PMA supplement)AVITA Medical, Inc.

    Supplement type: Normal 180 Day Track. Product code: OZA. Advisory committee: MI. Decision: APPR

    full page →fda device pma ↗
    ›Feb 5, 2026device pma189d agoQ-Med AB — Restylane Lyft with Lidocaine (PMA supplement)Sustained Therapeutics Inc

    Supplement type: 30-Day Notice. Product code: LMH. Advisory committee: SU. Decision: OK30

    full page →fda device pma ↗
    ›Feb 5, 2026device pma189d agoAbbott Vascular — XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Stent (PMA supplement)Postsurgical Therapeutics Inc

    Supplement type: 30-Day Notice. Product code: NIQ. Advisory committee: CV. Decision: OK30

    full page →fda device pma ↗
    ›Feb 5, 2026device recall189d agoDiagnostica Stago, Inc. device recall (Cls II)

    Brand Name: STA Liatest D-Di Product Name: STA Liatest D-Di Model/Catalog Number: REF 00515 Product Description: The STA¿ - Liatest ¿ D-Di kit is an immuno-turbidimetric assay for the quantitative determination of D-dimer in venous plasma (in 3.2 % sodium citrate) for use on STA-R¿, STA Compact¿ and STA Satellite¿ analyzers by professional laboratory personnel. The STA¿ - Liatest¿ D-Di is intended for use in conjunction with a clinical pretest probability (PTP) assessment model to exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) in outpatients suspected of PE or DVT. Component: No — Reason: After receiving customer complaints, investigations confirmed the presence of a positive bias in D-Dimer measurements throughout the entire analytical range. — Status: Ongoing

    full page →fda device recalls ↗
    ›Feb 5, 2026device recall189d agoRemel, Inc device recall (Cls II)

    Campy CVA Medium 100/PK, R01272 — Reason: Customer complaints report low to no recovery of Campylobacter Jejuni ATCC 33291 on identified lot of medium. — Status: Ongoing

    full page →fda device recalls ↗
    ›Feb 5, 2026grant189d agoBECKMAN RESEARCH INSTITUTE/CITY OF HOPE — Molecular Mechanisms Governing Non-canonical miR-146a BiogenesisCity of Hope

    AI grant. $489,500. PI: Mark P Boldin

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoUNIVERSITY OF WISCONSIN-MADISON — A chromatin loop controls the expression of anterograde transport genes durin...

    AI grant. $524,626. PI: DONNA M NEUMANN

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoINDIANA UNIVERSITY INDIANAPOLIS — Critical Crystal-Bacteria and Host Interactions Contributing to Kidney Stone ...

    DK grant. $728,742. PI: Qunfeng Dong

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoUNIVERSITY OF WASHINGTON — Early Ultrafiltration for Patients Initiating HemodialysisUniversity of Washington

    DK grant. $773,901. PI: BRYAN R KESTENBAUM

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoVANDERBILT UNIVERSITY — Understanding dynamics and phenotypic consequences of clonal hematopoiesis ca...

    AG grant. $35,593. PI: Yash Pershad

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoUNIVERSITY OF IOWA — Predicting Cognitive Outcomes from Stroke Using Lesion LocationUniversity of Iowa

    NS grant. $582,252. PI: Aaron D Boes

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoBRIGHAM AND WOMEN'S HOSPITAL — Th2 Memory in Chronic Type 2 InflammationBrigham and Women's Hospital

    AI grant. $3,080,416. PI: Patrick Joseph Brennan

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoNATIONAL JEWISH HEALTH — Uncovering the role of resident memory T cell in chronic lung disease viral i...

    AI grant. $470,219. PI: Fabienne Gally

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoVERSITI BLOOD HEALTH, INC. — Role of Force-directed Lipid Metabolism in the Endothelial-to-Hematopoietic T...

    DK grant. $127,500. PI: Wade William Sugden

    full page →nih reporter ↗
    ›Feb 5, 2026grant189d agoUNIVERSITY OF ILLINOIS AT CHICAGO — Extracellular Vesicle Inspired Nano Vesicles for CRISPR-based Targeting of MRSA

    AI grant. $440,908. PI: Francis Alonzo

    full page →nih reporter ↗
    ← prev
    page 11 of 187
    next →
    $XRAY11.61-0.43%
    $RCEL7.8650-4.09%
    $ECR
    $PEN324.29-0.11%
    $CYTK76.50+0.06%